RYTM · Rhythm Pharmaceuticals
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Note written ·
The last three months
Up 0.8% since the close; the S&P 500 is down 9.4% over the same sessions. Figures in the note can cover a different window.
Daily closes, to . Red: the note's price line under the older rule, a daily close below $100.00, set on 18 November 2026. The pale line is the 50-day average, $98.08 on .
Price line
A daily close below $100, which would give back most of the gain since AstraZeneca's proposal was reported on 4 November 2026 and show the market pricing an end to talks; or a statement by Rhythm or AstraZeneca that talks have ended with no other bidder named.
A price line, set under the rules before kill lines became business results on 20 November 2026. It stays until the note's next read replaces it; a close through it only makes the note due for a fresh read.
Research onlyNot in the portfolio.
The business · as of
Rhythm Pharmaceuticals sells Imcivree (setmelanotide), a daily injection for rare forms of obesity: Bardet-Biedl syndrome, certain genetic deficiencies and, since 19 March 2026 in the US, acquired hypothalamic obesity. It sells through specialty channels in the US, Europe and Japan. Net product revenue was $92.1 million in the quarter to 30 September 2026, with 73% of it from the US.
What is changing, and what follows · as of
- What is changing now
- On 4 November 2026 Reuters and the Wall Street Journal reported a non-binding AstraZeneca proposal of $124 a share upfront, up to $134 with milestones (about $10 billion). A report of a second bidder followed on 6 November 2026.
- What follows for the company
- Without a deal, Rhythm funds itself: $320.9 million in cash on 30 September 2026 (before a $250 million term-loan draw and a $70 million LG Chem payment), 2026 non-GAAP operating spending guided at $360–380 million.
- What follows for its customers, suppliers and competitors
- AstraZeneca (AZN) would gain a rare-obesity franchise for its Alexion unit. Novo Nordisk (NVO), the obesity-drug leader named in deal coverage, faces a larger rival in rare obesity if a deal is signed.
What the price assumes · as of
At the 17 November 2026 close (filed inputs to 3 November 2026) the shares trade at EV/sales 28.0 and P/B 91.9, for an enterprise value of $7,866 million; EV/EBIT and P/E are not meaningful. That holds only if revenue keeps growing near the 79.6% of the latest filed quarter while the −42.6% operating margin turns positive, or if the reported AstraZeneca proposal becomes a signed deal.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 3 November 2026; valuation at the 20 November 2026 close
The last six quarters
- Revenue, latest quarter ($M)
- 92.1
- Revenue, change on a year (%)
- +79.6
- Gross margin (%)
- 86.8
- Operating margin (%)
- −42.6
- Net cash, cash less debt ($M)
- 218
- Enterprise value to sales (×)
- 27.0
All filed numbers
What Rhythm Pharmaceuticals reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 92.1 | +79.6 | 86.8 | −42.6 |
| first filed | 71.3 | +46.9 | 87.5 | −68.1 |
| first filed | 60.1 | +83.8 | 88.1 | −87.1 |
| first filed | 57.3 | +36.9 | 91.6 | −82.2 |
| first filed | 51.3 | +54.3 | 89.3 | −102.6 |
| first filed | 48.5 | +66.8 | 88.6 | −93.4 |
| Pre-tax income ($M) | −40.8 |
|---|---|
| Net income ($M) four quarters: −194 | −41.4 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +4.2 |
| Operating cash flow ($M) | −81.8 |
|---|---|
| Capital spending ($M) | Not available |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 321 |
|---|---|
| Debt ($M) non-current long-term debt plus current maturities | 103 |
| Net cash, cash less debt ($M) | 218 |
| Deferred revenue ($M) | 0.0 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 39.1 |
| Inventory ($M) | 31.2 |
| Shareholders' equity ($M) | 88.0 |
| Market value ($M) | 7,790 |
|---|---|
| Enterprise value, market value plus net debt ($M) | 7,572 |
| Enterprise value to sales (×) | 27.0 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 88.6 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 16.8% of shares outstanding sold short, 23.3 days of average trading to cover, +6.1% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 days | Not available yet | Not available yet |
| 12 months | Not available yet | Not available yet |
Linked companies · as of
- Competitors:
- NVO
The thesis
Rhythm Pharmaceuticals is rated Medium: the shares are modestly more likely than not to beat the S&P 500 over the next three months. AstraZeneca's reported takeover proposal of $124 a share upfront sits above the $116.61 close of 17 November 2026, and the business behind it grew sales 80% from a year earlier in the third quarter. A signed merger agreement, or a statement that talks have ended, settles the call. No date is set for either.
The case rests on a proposal that neither company has confirmed. Reuters reported on 4 November 2026 that AstraZeneca made a non-binding offer worth about $10 billion, up to $134 a share including milestone payments. The Wall Street Journal reported the same day that the $124 offer was made in October. Analysts at Jefferies, Leerink and William Blair told Fierce Pharma that a bidding war could follow and that Rhythm is unlikely to accept the current terms. A report of an additional bidder followed on 6 November 2026.
The standalone business supports a floor under the price that sits well above where the shares traded before the reports. Imcivree (setmelanotide) is now approved in the US for acquired hypothalamic obesity, and that launch drove a 32% rise in US sales from the previous quarter in the quarter to 30 September 2026, the company's 8-K of 3 November 2026 shows.
The rating is Medium rather than High because the outcome is two-sided. A signed deal at or above the reported price would most likely carry the shares past the index. If talks collapse, the shares lose most of the gain from the 4 November 2026 report.
Bullish and bearish views on Rhythm Pharmaceuticals, Inc.
The bull case on Rhythm Pharmaceuticals, Inc. (RYTM), in brief: reported offer sits above the price. The bear case: the proposal is unconfirmed and non-binding.
Bull case
- Reported offer sits above the price. The Wall Street Journal reported a $124-a-share AstraZeneca offer, and Reuters reported up to $134 including milestones, on 4 November 2026. The shares closed at $116.61 on 17 November 2026.
- Signs of competing interest. Company news on 6 November 2026 carried a report of an additional bidder. Jefferies, Leerink and William Blair analysts said a bidding war could be brewing, Fierce Pharma reported in early November 2026.
- Hypothalamic obesity launch is working. Rhythm had more than 700 patient start forms for acquired hypothalamic obesity from more than 500 prescribers by 30 September 2026, about six months after the FDA approval of 19 March 2026, its third-quarter 8-K shows.
- Revenue growth is speeding up. Third-quarter 2026 net product revenue was $92.1 million, against $51.3 million a year earlier, and nine-month revenue was $223.5 million against $137.5 million, the 8-K of 3 November 2026 reports. The operating margin narrowed to −42.6% in the quarter from −102.6% a year earlier, filed figures show.
- More markets and indications are coming. Japan launched Imcivree for acquired hypothalamic obesity on 13 October 2026, Health Canada approved it on 22 September 2026, and NICE (England's National Institute for Health and Care Excellence) issued positive guidance for adults with Bardet-Biedl syndrome on 4 November 2026. Rhythm guides to a pivotal Phase 3 start for its oral drug bivamelagon in acquired hypothalamic obesity by the end of 2026.
Bear case
- The proposal is unconfirmed and non-binding. Neither Rhythm nor AstraZeneca has commented on the reports of 4 November 2026. Part of the reported $134 depends on milestones, so the guaranteed portion is the $124 the Wall Street Journal cited.
- Revenue fell short of the analyst estimate. Third-quarter revenue of $92.1 million came in below the $98.74 million analyst estimate, GuruFocus reported on 3 November 2026.
- Gross margin is slipping. Gross margin fell to 86.8% in the quarter to 30 September 2026, from 91.6% in the quarter to 31 December 2025, filed figures show.
- Losses and dilution continue. Net loss was $41.4 million in the third quarter and $194 million over the four quarters to 30 September 2026. The diluted share count rose 4.2% from a year earlier, and operating cash flow was −$82 million over those four quarters, the 10-Q filed 3 November 2026 shows.
- Insiders sold below the reported offer. Chief Executive David Meeker sold 50,000 shares at an average $102.67 on 14 September 2026, and Chief Financial Officer Hunter Smith sold 62,774 shares at an average $105.46 on 31 August 2026, both under Rule 10b5-1 plans and after option exercises, SEC Form 4 filings show.
Price setup · as of
The shares closed at $116.61 on 17 November 2026, up from $107.48 on 16 November 2026. That was the session after Rhythm released new clinical data for setmelanotide in acquired hypothalamic obesity. The closes from 10 November to 17 November 2026 ranged from $107.48 to $116.61, all above the $110.68 close of 4 November 2026 except two sessions. On 4 November 2026 the shares rose 28% on the takeover report, Reuters reported.
The reported $124 upfront price sits above the last close, and the 52-week intraday high is $122.20, set on 11 December 2025. The 50-day moving average is $97.27 and the 200-day moving average is $97.31, both as of 17 November 2026. The 52-week closing low is $75.82, set on 27 March 2026.
The 3-month change is 0.8%, against a reference close of $115.73 on 19 August 2026. The shares fell between August and early November and recovered on the takeover report. For stocks after a one-day jump of this size, no reliable effect on the following one or three months has been found so far. A common market view is that a gap between a stock's price and a reported offer measures how much the market doubts the deal. Here that gap is the distance between the $116.61 close and the reported $124.
Catalysts ahead
- ~31 December 2026 (est.): Start of the pivotal Phase 3 trial of bivamelagon in acquired hypothalamic obesity, guided for year-end 2026. Shows whether the oral follow-on to Imcivree stays on schedule. Its timing feeds into what a bidder pays and what the standalone pipeline is worth.
- ~January 2027 (est.): Preliminary fourth-quarter and full-year 2026 net product revenue. The first read on whether hypothalamic obesity demand keeps lifting US sales above the $67.5 million of the third quarter. That matters most if no deal is signed.
- ~February 2027 (est.): Fourth-quarter and full-year 2026 results and 2027 guidance. This report sets the standalone case if talks with AstraZeneca have not produced a signed agreement by then.
What would change the view
The risks this note tracks, each with what would confirm it:
- Talks with AstraZeneca end without a signed agreement and no rival bidder appears. Confirmed by: a statement by either company that discussions have ended, or a report that AstraZeneca has withdrawn its proposal.
- A deal is signed at terms close to the current price, with much of the value in contingent milestone payments. Confirmed by: an announced merger agreement whose upfront cash price is at or below the $124 the Wall Street Journal reported, with the rest paid as contingent value rights.
- The hypothalamic obesity launch slows after its first two quarters. Confirmed by: fourth-quarter 2026 US net product revenue at or below the $67.5 million of the third quarter.
- Gross margin keeps falling as the sales mix and ex-US pricing shift. Confirmed by: fourth-quarter 2026 gross margin below the 86.8% filed for the third quarter.
- Without a deal, losses and new debt lead to further dilution. Confirmed by: an equity offering, or a diluted share count rising faster than the 4.2% from a year earlier filed for the third quarter of 2026.
What it trades with · as of
The shares now trade on news about the takeover more than on the S&P 500 or the biotech sector. Reports on AstraZeneca (AZN) and its rare-disease unit Alexion, and any word of a rival bidder, move them most. Reuters reported on 4 November 2026 that AstraZeneca, valued at about $292 billion, would pursue the deal through Alexion.
Novo Nordisk (NVO) is named in deal coverage as the large obesity-drug competitor. Rhythm's market differs from Novo's mass-market drugs: it sells to patients with rare genetic and acquired forms of obesity. Without a deal, the shares would trade on Imcivree's quarterly sales and on bivamelagon's Phase 3 progress.
Caveats
- The reported AstraZeneca proposal is non-binding, and neither company has confirmed it; part of the reported $134 a share depends on milestone payments. Reuters report, 4 November 2026 · as of
- The $320.9 million cash figure at 30 September 2026 excludes a $250 million initial term-loan draw and a $70 million payment due to LG Chem for bivamelagon. Rhythm third-quarter 2026 results, Form 8-K filed 3 November 2026 · as of
The evidence, claim by claim (8)
- Third-quarter 2026 net product revenue was $92.1 million, up 29% from the previous quarter, against $51.3 million a year earlier; US sales were $67.5 million and ex-US sales $24.7 million. Rhythm third-quarter 2026 results, Form 8-K filed 3 November 2026 · as of
- Rhythm had received more than 700 patient start forms for Imcivree in acquired hypothalamic obesity from more than 500 prescribers by 30 September 2026. Rhythm third-quarter 2026 results, Form 8-K filed 3 November 2026 · as of
- AstraZeneca made a non-binding proposal of up to $134 a share including milestones, about $10 billion in total; the Wall Street Journal reported a $124-a-share offer made in October. Reuters, 4 November 2026 · as of
- Rhythm shares closed up 28% at $110.68 on the day the AstraZeneca proposal was reported. Reuters, 4 November 2026 · as of
- Cash, cash equivalents and short-term investments were $320.9 million at 30 September 2026, which the company says funds planned operations for at least 24 months. Rhythm third-quarter 2026 results, Form 8-K filed 3 November 2026 · as of
- Gross margin was 86.8% in the quarter to 30 September 2026, against 91.6% in the quarter to 31 December 2025. Form 10-Q for the third quarter of 2026 · as of
- CEO David Meeker sold 50,000 shares at an average $102.67 on 14 September 2026 under a Rule 10b5-1 plan, after exercising options at $6.05. SEC Form 4, 14 September 2026 · as of
- CFO Hunter Smith sold 62,774 shares at an average $105.46 on 31 August 2026 under a Rule 10b5-1 plan, after exercising options at $25.79. SEC Form 4, 1 September 2026 · as of
Sources
- AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say · finance.yahoo.com ·
- RHYTHM PHARMACEUTICALS, INC. - Form 8-K - FY2026 · sec.gov
- AstraZeneca said to offer $10B to acquire Rhythm, analysts whisper of a bidding war · fiercepharma.com
- RHYTHM PHARMACEUTICALS, INC. - Form 10-Q - FY2026 · sec.gov
- Rhythm Pharmaceuticals Reports Q3 2026: Revenue of $92.1 Million Misses Estimates, EPS Loss of $(0.61) Beats Expectations · gurufocus.com
- AstraZeneca made a $10bn offer to buy Rhythm Pharmaceuticals · marketscreener.com
Related · shared themes
PVLA
Palvella Therapeutics
Palvella Therapeutics has pulled back from its record close while the FDA reviews QTORIN rapamycin for a 28 February 2027 decision, with no…
SVRA
Savara
Savara's shares are modestly more likely to beat the S&P 500 over three months as its lung drug Molbreevi nears the FDA's 22 November 2026…
CAPR
Capricor Therapeutics
Capricor Therapeutics' shares are more likely to lag the S&P 500 because deramiocel's approval faces an FDA panel that voted 9-3 against…
CRSP
CRISPR Therapeutics
CRISPR Therapeutics shares are more likely to lag the S&P 500 over three months: they set a 52-week closing low of $40.15 on 17 November…